Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitoring with vedolizumab (VDZ).
You may also like
Marcia Cross of 'Desperate Housewives' Opens Up on Anal Cancer
- April 21, 2019
(MedPage Today) — ActressRead more
GAP Regimen Tops Historical Data for Advanced Biliary Tract Ca
- April 20, 2019
(MedPage Today) — ResultsRead more